Dr. Meghan Perkins — Cancer biologist and IVD entrepreneur with postdoctoral experience across Institut Curie, EFS, Institut Imagine and UPEC. First R&D Manager at Innovhem — a bootstrapped IVD startup for sickle cell disease monitoring — where she led assay development end-to-end from concept to clinical validation. Proven track record of executing in resource-constrained environments and building scientific strategy from the ground up.

Microfluidics engineer and biophysics PhD with extensive experience in microfluidic systems, prototype development for drug discovery and lab-on-chip automation. Worked for the past 7 years leading EU-funded R&D projects, advancing technologies from TRL 3 to TRL 7 in a startup environment, delivering robust experimental platforms through hands-on problem solving.

 Co-founder and CEO of Kamet Ventures (AXA venture builder) — built and scaled multiple deep-tech and insurtech ventures from 0 to Series A (Qare, Padoa, IBEX, etc.). Track record in operational build-out, go-to-market strategy, and VC fundraising across France and EU.